NHS set to make progress in hip surgery with MI (minimally invasive) technique
This article was originally published in Clinica
A minimally invasive hip replacement technique performed by the UK National Health Service for the first time this week promises to significantly reduce post-operative hospitalisation, with important potential financial and clinical implications for this and other procedures.
You may also be interested in...
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.